Clinical observation of Zebutinib second-line treatment for mantle cell lymphoma
10.3969/j.issn.1673-9701.2024.29.017
- VernacularTitle:泽布替尼二线治疗套细胞淋巴瘤的临床观察
- Author:
Liujin QIU
1
;
Yongting LAI
;
Tao ZHAN
;
Wei XIAO
;
Qingfang ZENG
Author Information
1. 赣州市肿瘤医院内科中心三区,江西赣州 341000
- Keywords:
Mantle cell lymphoma;
Second line treatment;
Zebutinib;
Clinical efficacy
- From:
China Modern Doctor
2024;62(29):69-72,91
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of second-line treatment with Zebutinib for mantle cell lymphoma.Methods Totally 80 patients with mantle cell lymphoma admitted to Ganzhou Cancer Hospital from October 2020 to December 2021 were divided into observation group and control group by lottery method,40 cases in each group.The control group received first-line treatment combined Bendamustine for mantle cell lymphoma,while the observation group received second-line treatment combined with Zebutinib on the basis of first-line treatment.The patients were followed up for 2 years.The clinical efficacy,tumor marker levels,immune function,survival cycle and treatment safety of two groups were evaluated and compared.Results The objective remission rate and disease control rate of observation group were higher than those of control group(P＜0.05).After treatment,the levels of lactate dehydrogenase,β2-microglobulin and carcinoembryonic antigen of observation group were lower than those of control group(P＜0.05).After treatment,the immune function indicators of observation group was better than that of control group(P＜0.05).The progression free survival and overall survival of observation group were higher than those of control group(P＜0.05).Conclusion Zebutinib second-line treatment for mantle cell lymphoma has a good effect,can reduce tumor marker levels,improve patients immune function,prolong patients survival cycle,and has good treatment safety.
